» Articles » PMID: 19086959

Perianal Disease Predicts Changes in Crohn's Disease Phenotype-results of a Population-based Study of Inflammatory Bowel Disease Phenotype

Overview
Specialty Gastroenterology
Date 2008 Dec 18
PMID 19086959
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The Montreal classification system of inflammatory bowel disease (IBD) provides a framework for describing disease phenotype.

Objective: We aimed to describe changes in IBD phenotype using the Montreal system and determine predictors of phenotype change in a Caucasian population-based cohort.

Methods: Ninety-two percent of people with IBD in Canterbury, New Zealand were recruited. Clinical notes were reviewed to confirm diagnosis and phenotype. Determinants of phenotype change were analyzed using multivariate analysis.

Results: A total of 1,420 (715 Crohn's disease [CD], 668 ulcerative colitis [UC]) patients with IBD were included. Median follow-up was 6.5 and 10.9 yr for CD and UC, respectively. Disease location remained stable in 91% of those with CD. Seventy-three percent of CD patients had inflammatory disease at diagnosis with the proportion of patients with complicated disease increasing over time. Progression to complicated disease was more rapid in those with small bowel than colonic disease location, (P < 0.001). Perianal disease was a significant predictor of change in CD behavior (HR 1.62, P < 0.001). Younger UC patients were more likely to have extensive disease at diagnosis than older patients (P < 0.001).

Conclusions: Although CD location remains relatively stable, behavior changes over time. Perianal disease is a strong predictor of developing more complicated CD. Proctitis is most common in UC patients at diagnosis although younger patients are more likely than older patients to have extensive disease. The Montreal classification provides a clinically useful framework for both researchers and clinicians.

Citing Articles

Application Value of Endoscopic Ultrasonography in Diagnosis and Treatment of Inflammatory Bowel Disease.

Jiang Y, Shi R, Zhou P, Lei Y, Cai Z, Sun Y Dig Dis Sci. 2024; 70(1):89-99.

PMID: 39614026 DOI: 10.1007/s10620-024-08751-9.


Perianal Crohn's disease: Still more questions than answers.

Swaminathan A, Sparrow M World J Gastroenterol. 2024; 30(39):4260-4266.

PMID: 39492828 PMC: 11525859. DOI: 10.3748/wjg.v30.i39.4260.


Progression of Crohn's Disease in Newly Diagnosed Patients: Results from an Observational Study Using US Claims Data.

Fan Y, Zhang L, Omidakhsh N, Bohn R, Putnam K, Adewale A Dig Dis Sci. 2024; 69(11):4167-4177.

PMID: 39438411 PMC: 11567996. DOI: 10.1007/s10620-024-08591-7.


Ten-year outcomes of a prospective population-based incidence cohort of inflammatory bowel disease patients from Canterbury, New Zealand.

Forbes A, Frampton C, Day A, DeVries M, McVicar N, Su H JGH Open. 2024; 8(10):e70038.

PMID: 39403112 PMC: 11472240. DOI: 10.1002/jgh3.70038.


Perianal fistulizing lesions of Crohn's disease are associated with long-term behavior and its transition: a Chinese cohort study.

Zhan W, Bai X, Yang H, Qian J Intest Res. 2024; 22(4):484-495.

PMID: 39005071 PMC: 11534454. DOI: 10.5217/ir.2024.00021.